Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

275.42 -2.46 (-0.89%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amgen

< Previous 1 2 3 4 5 Next >
ROSEN, A LEADING LAW FIRM, Encourages Amgen Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AMGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
AMGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Files Securities Class Action Lawsuit Against Amgen Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Match, Credit Suisse, SVB, and Amgen and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Notifies Amgen Inc. (AMGN) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Attention Amgen Inc. (AMGN) Shareholders: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed against Amgen Inc. and Encourages Investors with Significant Losses to Contact the Firm
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Amgen Inc. (AMGN) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Amgen Inc. (AMGN) Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Amgen Inc. (AMGN) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Amgen Inc. (AMGN) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Amgen Inc. (AMGN) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Amgen Inc. (AMGN) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Amgen Inc. (NASDAQ: AMGN)
From Bernstein Liebhard LLP
Via GlobeNewswire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
AMGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Amgen Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Amgen Inc. (AMGN) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Amgen Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Amgen Inc. (AMGN)
From Robbins LLP
Via Business Wire
Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
Avid Bioservices Inc. (NASDAQ: CDMO) is a contract development and manufacturing organization (CDMO) that specializes in producing monoclonal antibodies, 
Via MarketBeat
Exposures COVID-19
AMGN EQUITY ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Amgen Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – AMGN
From The Rosen Law Firm, P.A.
Via Business Wire
AMGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Amgen Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Is Amazon a Blue Chip Stock?
Is Amazon a blue chip stock or does it fit into a different category? Learn more about Amazon.com Inc. and how to categorize it with MarketBeat. 
Via MarketBeat
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
Harpoon Therapeutics Remains Volatile After Promising News
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%. 
Via MarketBeat
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 15, 2022 – USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech... 
Via FinancialNewsMedia
Topics Death
Exposures Death
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. 
Via MarketBeat
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up. 
Via TheNewswire.com
Exposures Product Safety
Merck Nears Breakout Point After October Surprise Good News
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments. 
Via MarketBeat
Topics Stocks
Exposures US Equities
MarketBeat: Week in Review 10/10-10/14
A volatile week is ending with the market moving lower. Here are some of the stories the MarketBeat analysts were covering this week. 
Via MarketBeat
Exposures COVID-19
Amgen Shares Leap Higher On Upbeat Outlook For Obesity Treatment
Shares of Amgen soared 5.72% Tuesday and added to those gains Wednesday. The gap-up followed a Morgan Stanley upgrade and increase to the price target. 
Via MarketBeat
Two Appealing Biotech Stocks for Two Distinct investors
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.